Low thyroid function is associated with an increased risk of advanced fibrosis in patients with metabolic dysfunction-associated fatty liver disease

被引:6
|
作者
Fan, Hong [1 ,2 ,3 ,4 ]
Li, Lili [1 ,2 ,5 ]
Liu, Zhenqiu [4 ,6 ,7 ,8 ]
Zhang, Pengyan [1 ,2 ,3 ,4 ]
Wu, Sheng [1 ,2 ,3 ]
Han, Xinyu [1 ,2 ,3 ]
Chen, Xingdong [3 ,4 ,6 ,7 ,8 ]
Suo, Chen [1 ,2 ,3 ,4 ]
Cao, Liou [5 ]
Zhang, Tiejun [1 ,2 ,3 ,4 ]
机构
[1] Fudan Univ, Sch Publ Hlth, Dept Epidemiol, Shanghai 200032, Peoples R China
[2] Fudan Univ, Key Lab Publ Hlth Safety, Minist Educ, Shanghai, Peoples R China
[3] Fudan Univ, Shanghai Inst Infect Dis & Biosecur, Sch Publ Hlth, Shanghai, Peoples R China
[4] Fudan Univ, Taizhou Inst Hlth Sci, Taizhou, Peoples R China
[5] Affiliated Shanghai Univ Med & Hlth Sci, Jiading Dist Cent Hosp, Shanghai 200032, Peoples R China
[6] Fudan Univ, Sch Life Sci, State Key Lab Genet Engn, Shanghai 200438, Peoples R China
[7] Fudan Univ, Collaborat Innovat Ctr Genet & Dev, Sch Life Sci, Shanghai 200438, Peoples R China
[8] Fudan Univ, Human Phenome Inst, 825 Zhangheng Rd, Shanghai, Peoples R China
关键词
Fatty liver disease; MAFLD; Fibrosis; Low-normal thyroid function; Subclinical hypothyroidism; NONALCOHOLIC STEATOHEPATITIS; SUBCLINICAL HYPOTHYROIDISM; EUTHYROID SUBJECTS; NATIONAL-HEALTH; HORMONES; NAFLD;
D O I
10.1186/s12876-022-02612-3
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Aims Observational studies showed that low thyroid function may perturb liver function. We aimed to evaluate the association of low thyroid function with both metabolic dysfunction-associated fatty liver disease (MAFLD) and advanced hepatic fibrosis.Methods Participants who underwent abdominal ultrasonography and thyroid function test in a Chinese hospital from 2015 to 2021were enrolled. Fibrosis-4 index (FIB-4) > 2.67 and/or non-alcoholic fatty liver disease fibrosis score (NFS) > 0.676 were used to define advanced fibrosis. Descriptive analyses were performed to characterize the epidemiology of MAFLD according to levels of thyroid-stimulating hormone (TSH). The logistic regression model was applied to estimate the association of low thyroid function with MAFLD and advanced fibrosis.Results A total of 19,946 participants (52.78% males, mean age: 47.31 years, 27.55% MAFLD) were included, among which 14,789 were strict-normal thyroid function, 4,328 were low-normal thyroid function, 829 were subclinical hypothyroidism. TSH levels were significantly higher in MAFLD patients with a FIB-4 > 2.67 and /or NFS > 0.676 than their counterparts. The logistic regression model adjusted for age and sex showed that low-normal thyroid function increased the risk of MAFLD (odds ratio [OR] = 1.09; 95% confidence interval [CI] 1.01-1.18). Multivariable regression model adjusted for age, sex, body mass index, type 2 diabetes, and hypertension showed low-normal thyroid function increased the risk of advanced fibrosis in patients with MAFLD (FIB-4 > 2.67: OR = 1.41, 95% CI 1.02-1.93; NFS > 0.676: OR = 1.72, 95% CI 1.08-2.72).Conclusion Elevated TSH concentrations are associated with advanced hepatic fibrosis, even in the euthyroid state.
引用
收藏
页数:8
相关论文
共 50 条
  • [41] Galectin-3 and Severity of Liver Fibrosis in Metabolic Dysfunction-Associated Fatty Liver Disease
    Sotoudeheian, Mohammadjavad
    PROTEIN AND PEPTIDE LETTERS, 2024, 31 (04): : 290 - 304
  • [42] Liver Fibrosis Scores and Coronary Artery Disease: Novel Findings in Patients with Metabolic Dysfunction-Associated Fatty Liver Disease
    Lu, Chuan
    Chen, Yan
    Zhang, Yue
    Zhao, Xin
    DIABETES METABOLIC SYNDROME AND OBESITY, 2023, 16 : 2627 - 2637
  • [43] Metabolic Dysfunction-associated Fatty Liver Disease is Associated with Greater Impairment of Lung Function than Nonalcoholic Fatty Liver Disease
    Miao, Lei
    Yang, Li
    Guo, Li-Sha
    Shi, Qiang-Qiang
    Zhou, Teng-Fei
    Chen, Yang
    Zhang, Huai
    Cai, Hui
    Xu, Zhi-Wei
    Yang, Shuan-Ying
    Lin, Hai
    Cheng, Zhe
    Zhu, Ming-Yang
    Nan, Xu
    Huang, Shuai
    Zheng, Ya-Wen
    Targher, Giovanni
    Byrne, Christopher D.
    Li, Yu-Ping
    Zheng, Ming-Hua
    Chen, Cheng-Shui
    JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2022, 10 (02) : 230 - 237
  • [44] Risk scores for metabolic dysfunction-associated fatty liver disease in pediatric obesity
    Lischka, Julia
    Lieb, Katharina
    Schanzer, Andrea
    Hojreh, Azadeh
    Ba-Ssalamah, Ahmed
    de Gier, Charlotte
    Walleczek, Nina-Katharina
    Zeyda, Maximilian
    Greber-Platzer, Susanne
    ANNALS OF NUTRITION AND METABOLISM, 2022, 78 (05) : 247 - 254
  • [45] Risk Factors for the Development of Metabolic Dysfunction-Associated Fatty Liver Disease in Mexico
    Tellez, S.
    Lopez, G.
    Gonzalez, M.
    Contreras, R.
    ANNALS OF NUTRITION AND METABOLISM, 2024, 80 : 138 - 139
  • [46] Metabolic dysfunction-associated fatty liver disease and low muscle strength: A comment
    Karim, Masood Muhammad
    Butt, Amna Subhan
    WORLD JOURNAL OF GASTROENTEROLOGY, 2024, 30 (17) : 2371 - 2373
  • [47] Metabolic dysfunction-associated fatty liver disease and the risk of 24 specific cancers
    Liu, Zhenqiu
    Lin, Chunqing
    Suo, Chen
    Zhao, Renjia
    Jin, Li
    Zhang, Tiejun
    Chen, Xingdong
    METABOLISM-CLINICAL AND EXPERIMENTAL, 2022, 127
  • [48] Association between depression and metabolic dysfunction-associated fatty liver disease/significant fibrosis
    Kim, Donghee
    Dennis, Brittany B.
    Cholankeril, George
    Ahmed, Aijaz
    JOURNAL OF AFFECTIVE DISORDERS, 2023, 329 : 184 - 191
  • [49] Increased risk of cancers in metabolic dysfunction-associated steatotic liver disease and MetALD
    Park, Yewan
    Jung, Jooyi
    Kim, Gi-Ae
    JOURNAL OF HEPATOLOGY, 2024, 80 : S468 - S468
  • [50] Cardiovascular Risk Reduction in Metabolic Dysfunction-Associated Steatotic Liver Disease and Metabolic Dysfunction-Associated Steatohepatitis
    Bernhard, Johannes
    Galli, Lukas
    Speidl, Walter S.
    Krychtiuk, Konstantin A.
    CURRENT CARDIOLOGY REPORTS, 2025, 27 (01)